CORT · Corcept Therapeutics Inc
$114.47
+3.96 (+3.58%)
At close · Aug 14
Market Cap
$12.37B
Shares
108.10M
Corcept Therapeutics Inc Earnings Call Transcripts
Every quarterly earnings call for Corcept Therapeutics Inc (CORT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲5.8%
$101.73M
$34.61M
'22 Q3
22-11-03
▲4.3%
$103.06M
$16.60M
'22 Q4
23-02-28
▲12.8%
$105.65M
$15.88M
'23 Q1
23-05-03
▲13.9%
$117.72M
$27.53M
'23 Q2
23-08-02
▲21.5%
$123.60M
$31.38M
'23 Q3
23-11-01
▲31.4%
$135.41M
$31.36M
'23 Q4
24-02-15
▲39%
$146.81M
$27.76M
'24 Q1
24-05-01
▲39.1%
$163.80M
$35.49M
'24 Q2
24-07-29
▲47.7%
$182.55M
$47.21M
'24 Q3
24-10-30
▲34.3%
$181.89M
$30.75M
'24 Q4
25-02-26
▲7.1%
$157.21M
$20.55M
'25 Q1
25-05-05
▲18.7%
$194.43M
$35.15M
'25 Q2
25-07-31
▲13.7%
$207.64M
$19.67M
'25 Q3
25-11-04
▲11.1%
$202.12M
$24.29M
'25 Q4
26-02-24
▲4.9%
$164.90M
−$31.76M
'26 Q1
26-04-30
LATEST
▲31.7%
$256.15M
$42.99M
'26 Q2
26-07-29
Earnings call
FY26 · Q2
2026-07-29
Corcept Therapeutics Q2 2026 Earnings Conference Call
Confident tone
Lifioli (Relacorilant/IBSO) oncology launch
Catalyst and Momentum clinical trial impact
Hyper cortisolism disease awareness / screening
Revenue
$256.15M
▲ 31.7% YoY Diluted EPS
$0.36
▲ 24.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Corcept Therapeutics Inc Q1 FY2026 Earnings Call
Confident tone
Hypercortisolism/Cushing's franchise (Korlym)
LeFioli (platinum-resistant ovarian cancer) launch
Revenue guidance and financial outlook
Revenue
$164.90M
▲ 4.9% YoY Diluted EPS
$-0.30
▼ 276.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Corcept Therapeutics Inc Q4 FY2025 Earnings Call
Cautious tone
Pharmacy vendor transition disruption
FDA rejection of relacorilant for Cushing's syndrome
Relacorilant oncology program (ROSELLA)
Revenue
$202.12M*
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Corcept Therapeutics Inc Q3 FY2025 Earnings Call
Confident tone
Hypercortisolism (Coral) Commercial Growth
Ovarian Cancer / Oncology Pipeline
MASH (MONARCH) and Other Pipeline
Revenue
$207.64M
▲ 13.7% YoY Diluted EPS
$0.16
▼ 61% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Corcept Therapeutics Inc Q2 FY2025 Earnings Call
Confident tone
CATALYST trial and disease awareness
ALS and liver disease pipeline
Ovarian cancer (Rosella/BELLA) program
Revenue
$194.43M
▲ 18.7% YoY Diluted EPS
$0.29
▼ 9.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Corcept Therapeutics Inc Q1 FY2025 Earnings Call
Confident tone
Hypercortisolism screening expansion and CATALYST study
Relacorilant NDA and launch readiness
Oncology platform (ROSELLA) and broader pipeline
Revenue
$157.21M
▲ 7.1% YoY Diluted EPS
$0.17
▼ 32% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Corcept Therapeutics Inc Q4 FY2024 Earnings Call
Confident tone
Relacorilant NDA and clinical efficacy
CATALYST study and market expansion
ROSELLA ovarian cancer trial
Revenue
$181.89M*
▲ 34.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Corcept Therapeutics Inc Q3 FY2024 Earnings Call
Confident tone
Relacorilant NDA submission for Cushing's syndrome
Safety and tolerability of relacorilant
CATALYST Phase 4 trial in difficult-to-control diabetes
Revenue
$182.55M
▲ 47.7% YoY Diluted EPS
$0.41
▲ 46.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-29
Corcept Therapeutics Inc Q2 FY2024 Earnings Call
Confident tone
Relacorilant GRACE trial
Korlym commercial growth
CATALYST prevalence study
Revenue
$163.80M
▲ 39.1% YoY Diluted EPS
$0.32
▲ 28% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Corcept Therapeutics Inc Q1 FY2024 Earnings Call
Confident tone
Relacorilant GRACE study (Cushing's)
Korlym commercial growth
CATALYST study / hypercortisolism awareness
Revenue
$146.81M
▲ 39% YoY Diluted EPS
$0.25
▲ 78.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Corcept Therapeutics Inc Q4 FY2023 Earnings Call
Confident tone
Relacorilant pipeline (GRACE, GRADIENT, NDA)
Korlym franchise and generic entry preparedness
CATALYST Phase 4 prevalence study
Revenue
$135.41M*
▲ 31.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Corcept Therapeutics Inc Q3 FY2023 Earnings Call
Revenue
$123.60M
▲ 21.5% YoY Diluted EPS
$0.28
▼ 6.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Corcept Therapeutics Inc Q2 FY2023 Earnings Call
Revenue
$117.72M
▲ 13.9% YoY Diluted EPS
$0.25
▲ 4.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Corcept Therapeutics Inc Q1 FY2023 Earnings Call
Revenue
$105.65M
▲ 12.8% YoY Diluted EPS
$0.14
▼ 30% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Corcept Therapeutics Inc Q4 FY2022 Earnings Call
Revenue
$103.06M*
▲ 4.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Corcept Therapeutics Inc Q3 FY2022 Earnings Call
Revenue
$101.73M
▲ 5.8% YoY Diluted EPS
$0.30
▲ 25% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Corcept Therapeutics Inc Q2 FY2022 Earnings Call
Revenue
$103.39M
▲ 12.9% YoY Diluted EPS
$0.24
▲ 14.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Corcept Therapeutics Inc Q1 FY2022 Earnings Call
Revenue
$93.69M
▲ 17.9% YoY Diluted EPS
$0.20
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Corcept Therapeutics Inc Q4 FY2021 Earnings Call
Revenue
$98.82M*
▲ 15.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Corcept Therapeutics Inc Q3 FY2021 Earnings Call
Revenue
$96.13M
▲ 11.4% YoY Diluted EPS
$0.24
▲ 41.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Corcept Therapeutics Inc Q2 FY2021 Earnings Call
Revenue
$91.59M
▲ 3.4% YoY Diluted EPS
$0.21
▼ 8.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Corcept Therapeutics Inc Q1 FY2021 Earnings Call
Revenue
$79.44M
▼ 14.8% YoY Diluted EPS
$0.18
▼ 28% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-08
Corcept Therapeutics Inc Q4 FY2020 Earnings Call
Revenue
$85.73M
▼ 2.5% YoY Diluted EPS
$0.20
▼ 16.7% YoY Gross margin
98.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-03
Corcept Therapeutics Inc Q3 FY2020 Earnings Call
Revenue
$86.33M
▲ 5.9% YoY Diluted EPS
$0.17
▼ 22.7% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Corcept Therapeutics Inc Q2 FY2020 Earnings Call
Revenue
$88.56M
▲ 22.6% YoY Diluted EPS
$0.23
▲ 35.3% YoY Gross margin
98.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-04
Corcept Therapeutics Inc Q1 FY2020 Earnings Call
Revenue
$93.25M
▲ 43.8% YoY Diluted EPS
$0.25
▲ 66.7% YoY Gross margin
98.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Corcept Therapeutics Inc Q4 FY2019 Earnings Call
Revenue
$87.89M
▲ 31.5% YoY Diluted EPS
$0.24
▲ 33.3% YoY Gross margin
98.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1088856
CUSIP
218352102
13F (30d)
390 filings
389 filers
Visit website
Investor relations